Click here to read the original notifications for Amiodarone hydrochloride tablets 100 mg & 200 mg, Flecainide Capsules 100 mg and 200mg, Sodium chloride Inj 0.9% 5ml, 10ml and 20ml  plus Propofol  Inj 10 mg 20 ml.

All of these products will have DUAL listings in the Pharmaceutical Schedule & where applicable HML from 1 July 2019 until 30 November 2019.

We ask that you continue to order the incumbent brand(s) to ensure supplies move through the supply chain with no risk to either pharmacy or wholesaler.

ProPharma /PWR will implement automatic replacement where applicable.

As of the date of this notification ProPharma / PWR cannot accept any of the products listed to be delisted for credit under any circumstances.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 December 2019 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesale and pharmacy, do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author